Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of long-term avapritinib in GIST
2020-005751-21Phase 4Completed
- Sponsor
- Blueprint Medicines
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of avapritinib in gastrointestinal stromal tumor (GIST), sponsored by Blueprint Medicines. Primary endpoint: Long-term safety of avapritinib. Started Feb 2021; status: completed.
02
Drugs
avapritinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2020-005751-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005751-21.